Professor Jennifer Taylor-Cousar of Denver, Colorado, spoke at the TSANZ 2024 annual meeting about how to provide care for people with cystic fibrosis who are not using CFTR modulators, whether because they have ineligible variants, side effects or cost barriers to access. She also looks forward to the novel nucleic acid-based therapies in the development pipeline that offer more hope for people with CF.